<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="to developing severe RSV disease receive passive antiviral immunization with" exact="palivizumab" post="in accordance to French guidelines [8]. Finally, our hospital"/>
 <result pre="of their ALRIs according to the 1999 marketing authorization of" exact="palivizumab" post="by the European Medicines Agency (EMA) [11], the 2007"/>
 <result pre="French Health Authority (HAS), [8] and the 2014 guidance for" exact="palivizumab" post="use of the American Academy of Pediatrics (AAP) [12]."/>
 <result pre="22 (9.2) 21 (9.2) 1 (9.1) Antiviral prophylaxis (n, %)" exact="palivizumab" post="6 (2.5) 6 (2.6) 0 (0.0) 1.0 i.v. or"/>
 <result pre="respectively (p &amp;lt; 0.0001). Among children with community-acquired RSV infections," exact="palivizumab" post="–based prophylaxis was given to 6/18 (33.3%), 6/6 (100%)"/>
 <result pre="versus 0.11%, p &amp;lt; 0.0001). No children with nosocomial RSVreceived" exact="palivizumab" post="–based prophylaxis prior to the onset of their infection."/>
 <result pre="of all RSV-infected inpatients revealed that no other patient required" exact="palivizumab" post="according to the 2007 French and the 2014 American"/>
 <result pre="of new and more cost-effective strategies against RSV infections than" exact="palivizumab" post="(including long acting monoclonal antibodies and vaccines), further larger"/>
 <result pre="Diseasescollab: American Academy of Pediatrics Bronchiolitis Guidelines CommitteeUpdated guidance for" exact="palivizumab" post="prophylaxis among infants and young children at increased risk"/>
</results>
